• Users Online: 538
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

 Table of Contents  
ORIGINAL ARTICLE
Year : 2019  |  Volume : 8  |  Issue : 2  |  Page : 277-283

Design and development of transdermal drug delivery of nonsteroidal anti-inflammatory drugs: Lornoxicam


Department of Pharmaceutics, KLE College of Pharmacy, Bengaluru, Karnataka, India

Date of Web Publication30-Oct-2019

Correspondence Address:
Dr. H N Shivakumar
Department of Pharmaceutics, KLE College of Pharmacy, Rajajinagar, Bengaluru 560010, Karnataka.
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jrptps.JRPTPS_51_19

Rights and Permissions
  Abstract 

Background: Conventional route, the most common route of administration, has drawbacks such as hepatic first-pass metabolism, poor bioavailability, and ability to alter drug concentrations in the blood. These problems can be overcome by a controlled-release drug delivery system, which can be accomplished with the development of transdermal drug delivery system. Objective: The objective of this study was to design and develop a lornoxicam-loaded matrix-type transdermal films with different permeation enhancers and determine their physicochemical characteristics. Materials and Methods: Lornoxicam-loaded transdermal films were prepared by the solvent evaporation technique. The Fourier transform infrared spectroscopic studies were performed to determine the drug–excipient interactions. Six formulations were prepared with different permeation enhancers such as propylene glycol, dimethylformamide, dimethyl sulfoxide (DMSO), sodium lauryl sulfate, Span 20, and TWEEN 80 by using 500 mg of sodium alginate as the polymer and 60% w/w glycerin as the plasticizer. The prepared formulations were evaluated for thickness, uniformity of weight, moisture loss, moisture uptake, drug content, and tensile strength. The effect of different permeation enhancers on diffusion was determined through a shed snakeskin by using Franz diffusion cells. Results: The preformulation studies conducted were fulfilled to design a matrix-type transdermal film. In vitro diffusion 24 h indicated that the steady state flux were in the order of F3 > F2 > F1 > F6 > F5 > F4. It was observed that the film prepared with DMSO showed higher diffusion than the formulations with other permeation enhancers. Conclusion: It was concluded that permeation enhancer to prepare lornoxicam-loaded matrix-type transdermal film to improve patient compliance.

Keywords: Dimethyl sulfoxide, glycerin, lornoxicam, sodium alginate, transdermal drug delivery systems


How to cite this article:
Shivakumar H N, Kotian RS. Design and development of transdermal drug delivery of nonsteroidal anti-inflammatory drugs: Lornoxicam. J Rep Pharma Sci 2019;8:277-83

How to cite this URL:
Shivakumar H N, Kotian RS. Design and development of transdermal drug delivery of nonsteroidal anti-inflammatory drugs: Lornoxicam. J Rep Pharma Sci [serial online] 2019 [cited 2019 Nov 15];8:277-83. Available from: http://www.jrpsjournal.com/text.asp?2019/8/2/277/269943




  Introduction Top


Conventional route, the most frequently used route of administration, has shortcomings such as hepatic first-pass metabolism, poor bioavailability, and ability to alter drug concentration in the blood.[1] These complications can be overcome by the controlled-release drug delivery systems, which ease the drug release at a predetermined rate.[2],[3] Controlled-drug delivery can be accomplished by transdermal drug delivery systems (TDDSs), which deliver drugs through the epidermis of the skin to attain the prolonged systemic circulation. The advantages of TDDS include increased patient compliance, maintained plasma drug concentration, enhanced bioavailability, no hepatic first-pass effect, sustained drug concentrations in the blood, and decreased side effects and gastrointestinal complications.[1],[4]

Lornoxicam, also called chlortenoxicam, belongs to the oxicam group of nonsteroidal anti-inflammatory drugs (NSAIDs). NSAIDs have highly potent analgesic and anti-inflammatory property.[5],[6] Lornoxicam is a widely recommended NSAID for the treatment of patients with rheumatoid arthritis and osteoarthritis.[5] Moreover, lornoxicam is poorly soluble in water and has short plasma half-life. Owing to these advantages, lornoxicam is chosen as an ideal candidate for controlled-drug delivery.[6]

Lornoxicam, similar to other NSAIDSs, decreases the prostaglandin synthesis by inhibiting the cyclooxygenase (COX) branch of the arachidonic acid pathway. It inhibits both isoforms of COX, that is, COX-1 and COX-2 in the same proportions.[7] Inhibition of (PG) synthesis protects the gastrointestinal mucosal membrane by preventing the gastric acid secretion and strengthening the mucosal barrier for gastric acid. However, the inhibition of PG synthesis may cause gastric side effects such as heartburn, mild dyspepsia, ulceration, and hemorrhage.[2]

Sodium alginate is a biopolymer that has been widely used as pharmaceutical agent in the formulation tablets as a binding and disintegrating agents.[8],[9] Sodium alginate in the presence of calcium chloride forms gel and delays the dissolution of a drug from sustained release formulations.[10] Although there are several permeation enhancers, dimethyl sulfoxide(DMSO) is considered as the ancient, safe, and effective molecule, facilitating the transdermal delivery of both hydrophilic as well as lipophilic medications.[11] Hence, in our study, lornoxicam-loaded transdermal patches were developed with sodium alginate (as a polymer) and different permeation enhancers to regulate the release of lornoxicam concentrations up to 24h.

Studies have formulated the transdermal patches of NSAIDs with different polymers and permeation enhancers.[12],[13] However, to the best of our knowledge, studies with lornoxicam loaded-transdermal patches in the management of arthritis were scarce. Hence, this study focused to develop a newly modified lornoxicam-loaded transdermal drug delivery films with different permeation enhancers and determine their physicochemical characteristics.


  Materials and Methods Top


Materials

Lornoxicam was procured from DM Pharma, Solan, Himachal Pradesh, India. The excipients such as sodium alginate, glycerin, methanol, potassium dihydrogen orthophosphate, sodium hydroxide pellets, calcium chloride, and DMSO were procured from S. D. Fine Chemicals, Mumbai, Maharashtra, India. Octanol was procured from Central Drug House, New Delhi, India.

Preformulation study

Preparation of stock and working standard solutions: An accurately weighed 50 mg of lornoxicam was dissolved in a slight amount of methanol and diluted with 50mL phosphate buffer (pH 7.4) to attain the concentration of 1 mg/mL. A standard stock solution of 0.4mL was drawn and diluted to 100mL with phosphate buffer (pH 7.4) to prepare secondary standard solution of concentration 40 μg/mL. A series of working standard solutions was prepared by withdrawing 0.1, 0.2, 0.3, 0.4, and 0.5mL of the secondary standard solution to attain the concentrations of 4, 8, 12, 16, and 20 μg/mL, respectively. The absorbance of the working standards was measured at 376 nm in a UV spectrophotometer with phosphate buffer (pH 7.4) as a blank. The obtained readings were plotted on the Figure, and the data were subjected to linear regression analysis in Microsoft Excel. The λmax obtained in this study was found to correspond well with that reported earlier.[14] The method developed was found to be sensitive, precise, and reliable.

Determination of melting point: A small amount of the drug (lornoxicam) was taken in a capillary tube closed at one end and placed in a melting point apparatus. The temperature at which the drug melted was recorded. This was repeated for at least three times and the average value was taken.

Determination of solubility: An excess amount of lornoxicam was taken and dissolved in a measured quantity of phosphate buffer (pH 7.4) in a glass vial to obtain a saturated solution. The solution was sonicated and kept at room temperature to attain equilibrium. After 24h, the solution was filtered and the concentration of lornoxicam in the filtrate was determined spectrophotometrically.[15]

Determination of partition coefficient: An accurately weighed 10 mg of lornoxicam was taken and dissolved in 10mL of 1-octanol (1 mg/mL). The 5mL of octanol solution was taken and equilibrated into 5mL of phosphate buffer (pH 7.4) in separating funnel and shaken intermittently and kept aside for 24h at room temperature. After 24h, the concentration of lornoxicam in the phosphate buffer was determined spectrophotometrically. The partition coefficient was determined by the following equation:[16]

[INLINE 1]

Permeability studies

Preparation of shed snakeskin: The epidermis of the skin was taken after shedding and sealed in a polyethylene bag at room temperature. Before conducting the diffusion study, the shed snakeskin was hydrated in 0.002% w/v aqueous sodium azide for three days.[17],[18]

Permeability studies using modified Franz diffusion cell: A standardized modified Franz-type diffusion cell consists of two compartments—donor compartment and receptor compartment. Different concentrations of drug in phosphate buffer were taken in donor compartment. The snake shed skin was mounted between the donor and receptor compartments. The phosphate buffer, as a medium, was taken in a receiver compartment to maintain the sink conditions. The medium was magnetically stirred at 600rpm to maintain a temperature of 37°C. The amount of drug diffused was withdrawn periodically at 0, 1, 2, 3, 5, 8, 12, and 24h and estimated spectrophotometrically at 376 nm.

Permeability coefficient: It is the velocity of drug passage through the skin or membrane (in µg/cm/h). The permeability coefficient[19] was determined from the slope of the Figure of percentage of drug versus time as follows:

[INLINE 2]

where, Vd = volume of donor solution and S = surface area of the tissue

Flux: Flux is defined as the amount of drug flowing through a unit cross-sectional barrier in unit time. It is calculated using the following equation:[20]

[INLINE 3]

where, CD = concentration of drug in the donor solution and P = permeability coefficient.

Preparation of transdermal films

Matrix films of sodium alginate containing lornoxicam were prepared by solvent-casting method. An accurately weighed 22 mg of lornoxicam was dissolved in a small amount of ethanol, and the solution was made up to 15mL with distilled water adjusted to pH of 7.4 with phosphate buffer. Sodium alginate was added to the aqueous solution of the drug and casted in a petri plate measuring 4.5cm in diameter. Glycerin was used as a plasticizer in a concentration of 60% w/w based on the dry weight polymer. After drying at room temperature for 48h, circular films of 1cm diameter, each containing 1 mg of the drug were taken cut out. Six different formulations containing different permeation enhancers were prepared as per [Table 1]. A 10% w/v solution of calcium chloride was prepared to harden the surfaces of the matrix films. The dried matrix films were wrapped in a butter paper and stored in a desiccator for further analysis.
Table 1: Composition of formulations

Click here to view


Drug–excipient interaction study

Fourier transform infrared studies: Infrared (IR) spectrophotometry is an analytical technique utilized to check the chemical interactions between the drug and the excipients used in the formulations. Here, 10-mg sample was powdered and mixed with powdered potassium bromide. The powdered mixture was taken in a diffuse reflectance sampler, and the spectrum was recorded by scanning in the wavelength region of 4000–400cm−1 in a Fourier transform infrared (FTIR) spectrophotometer. The IR spectrum obtained was compared with the IR spectrum of the pure drug to determine any possible drug–excipient interaction.[21]

Evaluation of transdermal films

All the prepared transdermal films were evaluated by the following parameters:[22],[23]

Thickness determination

The thickness of the films was measured at four different points by using Baker digital caliper, Evansville, Wisconsin (WI), United states. The average of four readings was taken to determine the thickness.

Uniformity of weight

Three different films of the individual batches were taken randomly and weighed to calculate the average weight. The individual weight of the film should not deviate from the average weight of the three films.

Moisture loss

The films were accurately weighed and placed in a desiccator containing calcium chloride at 40°C and dried at least for 24h. Then, the film was taken out and weighed repeatedly until it showed a constant weight. The percentage moisture loss was determined by the following formula:

[INLINE 4]

Moisture uptake

The weighed film kept in the desiccator at 40°C was taken out and exposed to relative humidity (RH) at 75% (saturated solution of sodium chloride) and 93% (saturated solution of ammonium hydrogen phosphate) in a desiccator. The weights were measured periodically till a constant weight was obtained. The percentage moisture uptake or absorption was determined by the following formula:

[INLINE 5]

Drug content

Transdermal films of the specified area (1.76cm2) were cut into pieces and taken in a 50-mL volumetric flask. Approximately 10mL of ethanol was added and shaken on a mechanical shaker to obtain a homogeneous solution. Then, 0.5mL of the solution was taken and diluted to 10mL with saline phosphate solution (pH 7.4) and filtered. The absorbance of the filtrate was measured at 376 nm by UV spectrophotometer.

Tensile strength

It was measured by universal strength testing machine. In this, maximum stress was applied at any point on the film until the film gets broken. The tensile strength was calculated by the maximum tensile strength applied at the break divided by the cross-sectional area of the film. The tensile strength was determined by the following formula:

[INLINE 6]

In vitro diffusion study

In vitro diffusion study was also carried out in a Franz diffusion cell. The conditions were maintained same as the permeability studies, but in this, lornoxicam-loaded transdermal films were placed in the donor compartment.[24]


  Results Top


Standard plot of lornoxicam

The absorbance values of the series of working standard solution are depicted in [Figure 1]. The curve was found to show a slope average of 0.053 with a regression coefficient of 0.9989. Beer–Lambert’s range was 0–20 µg/mL.
Figure 1: Standard curve of lornoxicam (n = 3) in phosphate buffer (pH 7.4)

Click here to view


Drug solubility pH

The solubility of the lornoxicam in buffer solutions of different pH levels is given in [Table 2].
Table 2: Solubility of lornoxicam at different pH levels

Click here to view


Melting point

The melting point of lornoxicam was found to be 225°C ± 0.028°C, represented as mean ± SD, n = 3 (SD = standard deviation).

Partition coefficient

The logarithmic P value (partition coefficient) of the lornoxicam was found to be 1.8 ± 1.21 in octanol and phosphate buffer (pH 7.4).

Permeability studies

The amount of lornoxicam diffused across the shed snakeskin using 2 and 5 mg/mL donor concentrations is presented in [Figure 2]. The permeability coefficient of lornoxicam was found to be 1.718 and 1.83cm/h for 2 and 5 mg/mL concentrations, respectively. The steady state flux of lornoxicam was found to be 3.43 and 3.73 μg/cm2/h at 2 and 5 mg/mL concentrations, respectively.
Figure 2: Permeation profile of lornoxicam (2 and 5 mg) across the shed snakeskin

Click here to view


Drug–excipient interaction study

The prominent peaks in lornoxicam and sodium alginate were also reflected in the mixture of lornoxicam with sodium alginate as shown in [Figure 3][Figure 4][Figure 5].
Figure 3: Fourier transform infrared spectroscopy spectrum of lornoxicam

Click here to view
,
Figure 4: Fourier transform infrared spectroscopy spectrum of sodium alginate film

Click here to view
,
Figure 5: Fourier transform infrared spectroscopy spectrum of lornoxicam and sodium alginate

Click here to view


Evaluation of transdermal films of lornoxicam

Thickness determination: [Figure 4] The thickness [Figure 5] of the six films with six different permeation enhancers varied from 0.300 ± 0.003 to 0.358 ± 0.003mm [Table 3].
Table 3: Physical characterization of lornoxicam films prepared

Click here to view


Uniformity of weight: The variations of weights ranged between 0.021 ± 0.007 and 0.025 ± 0.001g, which indicate that all the formulations were relatively similar [Table 3].

Moisture loss: The moisture loss ranged between 3.06% ± 0.102% and 4.04% ± 0.111% [Table 3].

Drug content: The drug content was found to be ranging between 0.902 ± 0.042 and 0.956 ± 0.063 mg [Table 3].

Tensile strength: The tensile strength of the films was found in the order of F1 > F2 > F4 > F5 > F6 > F3. The values varied between 1.41 ± 0.119 and 1.51 ± 0.120g/cm2 [Table 3].

Moisture uptake: The moisture absorption varied between 5.09%–7.12% and 8.95%–10.96% at RH 75% and 93%, respectively [Table 4].
Table 4: Determination of moisture uptake (in weight %) of different formulations (n = 3)

Click here to view


In vitro diffusion study: The diffusion profile of the six formulations prepared with six different permeation enhancers and the formulation without permeation enhancer is shown in [Figure 6] and [Figure 7]. The steady state flux [Figure 7] of the formulations is shown in [Table 5].
Figure 6: Comparison of amount of drug diffused from different formulations F0, F1, F2, and F3 through the shed snakeskin

Click here to view
,
Figure 7: Comparison of amount of drug diffused from different formulations F4, F5, and F6 through the shed snakeskin

Click here to view
,
Table 5: Steady state flux of transdermal formulation

Click here to view



  Discussion Top


The penetration of the drug into the lipid membrane depends on the partition coefficient. Partition coefficient determines the hydrophobicity of the chemical substance. Higher is the partition coefficient greater will be the penetration of drugs. The partition coefficient of lornoxicam of 1.8 ± 1.21 specifies that lornoxicam is an ideal candidate for TDDS.[25] However, success of the drug mainly depends on the ability of its penetration through the skin in required quantities to accomplish therapeutic effect.[26] Hence, in our study, lornoxicam-loaded transdermal patches with different permeation enhancers was prepared and evaluated to optimize the ideal formulation for transdermal drug delivery.

FTIR spectral studies did not reveal any significant chemical reaction between lornoxicam and sodium alginate. Thus, they indicate that lornoxicam and sodium alginate were compatible for the formulation of transdermal film. A similar combination studied by Hadi et al.[27] was also found to have no interaction between the drug and the polymer.

Thickness marginally varied between the patches, which indicated that thickness of patches depended on the amount of polymer. Tensile strength slightly varied between the patches, which indicated that patches were found to be flexible, strong, and not brittle. The uniform drug content and weight of lornoxicam films indicated the process used to formulate the patches was ideal and able to fabricate patches with uniform weight and drug content. Overall, it was perceived that thickness, weight uniformity, moisture loss, moisture uptake, and tensile strength was apt for the maximum strength of prepared formulations. A study conducted by Baviskar et al.,[28] with different permeation enhancers, reported similar physiochemical data.

In our study, DMSO showed increased steady flux and gave higher drug release when compared with other enhancers such as propylene glycol, dimethylformamide, sodium lauryl sulfate, Span 20, and TWEEN 80. Various studies also reported that DMSO was the widely used permeation enhancer to increase the penetration of drugs into the biological membrane.[29],[30],[31] Moreover, the drug permeation from transdermal patches through snake shed skin confirmed that lornoxicam could perhaps permeate through the human skin.

Overall, current investigation stated that the film of lornoxicam with sodium alginate as a polymer, glycerin as a plasticizer, and DMSO as a permeation enhancer was suitable for the formulation of transdermal film.


  Conclusion Top


The in vitro diffusion studies were carried out in the Franz diffusion by using the shed snakeskin. The amount of lornoxicam diffused increased in the following order: F4 < F5 < F6 < F1 < F2 < F3. From the order, it was confirmed that the amount of lornoxicam diffused from the F3 formulation by 24h, that is, 149.4 μg/cm2 was more when compared to other formulations.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Hayat S, Nawaz R A descriptive review on transdermal patches. World J Pharm Pharm Sci 2014;3:124-37.  Back to cited text no. 1
    
2.
Kavitha K, Mangesh R Design and evaluation of transdermal films of lornoxicam Int J Pharma Bio Sci 2011;2:54-62.  Back to cited text no. 2
    
3.
Sharma N, Agarwal G, Rana AC, Bhat ZA, Kumar D A review: Transdermal drug delivery system: A tool for novel drug delivery system. Int J Drug Develop Res 2011;3:1892-902.  Back to cited text no. 3
    
4.
Kshirsagar N Drug delivery systems. Indian J Pharmacol 2000;32:S54-61.  Back to cited text no. 4
    
5.
Patel M, Patel K, Patel N Formulation and in-vitro evaluation of pulsatile release tablet of lornoxicam. Am J PharmTech Res 2012;2:843-55.  Back to cited text no. 5
    
6.
Palei NN, Das MK Preparation and characterization of lornoxicam loaded solid lipid nanoparticles made from different lipids. Int J Pharm Pharm Sci 2013;5:438-442.  Back to cited text no. 6
    
7.
Zhang Y, Zhong D, Si D, Guo Y, Chen X, Zhou H Lornoxicam pharmacokinetics in relation to cytochrome P450 2c9 genotype. Br J Clin Pharmacol 2005;59:14-7.  Back to cited text no. 7
    
8.
Rajesh N, Siddaramaiah, Gowda D, Somashekar C Formulation and evaluation of biopolymer based transdermal drug delivery. Int J Pharm Pharm Sci 2010;2:142-7.  Back to cited text no. 8
    
9.
Sachan NK, Pushkar S, Jha A, Bhattcharya A Sodium alginate: The wonder polymer for controlled drug delivery. J Pharm Res 2009;2:1191-9.  Back to cited text no. 9
    
10.
Lewis S, Pandey S, Udupa N Design and evaluation of matrix type and membrane controlled transdermal delivery systems of nicotine suitable for use in smoking cessation. Indian J Pharm Sci 2006;68:179-84.  Back to cited text no. 10
    
11.
Marren K Dimethyl sulfoxide: an effective penetration enhancer for topical administration of NSAIDs. Phys Sportsmed 2011;39:75-82.  Back to cited text no. 11
    
12.
Modi C Effect of components (polymer, plasticizer and solvent) as a variable in fabrication of diclofenac transdermal patch. J Pharm Bioallied Sci 2012;4:S57-9.  Back to cited text no. 12
    
13.
Jadhav R, Kasture P, Gattani S, Surana S Formulation and evaluation of transdermal films of diclofenac sodium. Int J Pharm Tech Res 2009;1:1507-11.  Back to cited text no. 13
    
14.
Sahoo SK, Giri RK, Patil SV, Behera AR, Mohapatra R Development of ultraviolet spectrophotometric method for analysis of lornoxicam in solid dosage forms. Trop J Pharm Res 2012;11: 269-73.  Back to cited text no. 14
    
15.
Jamakandi VG, Mulla JS, Vinay BL, Shivakumar H Formulation, characterization, and evaluation of matrix-type transdermal patches of a model antihypertensive drug. Asian J Pharm 2009;3:59-65.  Back to cited text no. 15
    
16.
Kale P, Warrier H, Shrivastava R Preformulation stability and permeation studies of transdermal patches of salbutamol. Ind J Pharm Sci 1996;58:211-5.  Back to cited text no. 16
    
17.
Krishnaiah YS, Satyanarayana V, Karthikeyan RS Effect of the solvent system on the in vitro permeability of nicardipine hydrochloride through excised rat epidermis. J Pharm Pharm Sci 2002;5:123-30.  Back to cited text no. 17
    
18.
Mandal SC, Bhattacharyya M, Ghosal SK In-vitro release and permeation kinetics of pentazocaine from matrix dispersion type transdermal drug delivery systems. Drug Dev Ind Pharm 1994;20:1933-1941.  Back to cited text no. 18
    
19.
Patel HJ, Patel JS, Desai B, Patel KD Permeability studies of anti hypertensive drug amlodipine besilate for transdermal delivery. Asian J Pharm Clin Res 2010;3:31-4.  Back to cited text no. 19
    
20.
Brodin B, Steffansen B, Nielsen CU Molecular biopharmaceutics: Aspects of drug characterisation, drug delivery and dosage form evaluation. In:Bente S, Birger B, Carsten UN, editors. London, UK: Pharmaceutical Press;2010. 135-52 p.  Back to cited text no. 20
    
21.
Kutmalge M, Ratnaparkhi M, Jadhav A, Wattamwar M Formulation and in-vitro evaluation of lornoxicam floating microsphere. Scholars Res Lib 2014;6:169-83.  Back to cited text no. 21
    
22.
Sadhana PG, Jain S Effective and controlled transdermal delivery of metoprolol tartrate. Ind J Pharm Sci 2005;67:346-50.  Back to cited text no. 22
    
23.
Mutalik S, Udupa N Glibenclamide transdermal patches: Physicochemical, pharmacodynamic, and pharmacokinetic evaluations. J Pharm Sci 2004;93:1577-94.  Back to cited text no. 23
    
24.
Megrab NA, Williams AC, Barry BW Oestradiol permeation across human skin, silastic and snake skin membranes: The effect of ethanol/water co-solvent system. Int J Pharm 1995;116:101-12.  Back to cited text no. 24
    
25.
Kannan K, Sandhya K, Shafi S, Ramya D, Rahamath S, Manikanta G Formulation and evaluation of transdermal patches containing anti-inflammatory drug of lornoxicam. Indian J Biotech Pharm Res 2014;5:542-8.  Back to cited text no. 25
    
26.
Pathan IB, Setty CM Chemical penetration enhancers for transdermal drug delivery systems. Trop J Pharma Res 2009;8:173-179.  Back to cited text no. 26
    
27.
Hadi MA, Rao NG, Rao AS Formulation and evaluation of mini-tablets-filled-pulsincap delivery of lornoxicam in the chronotherapeutic treatment of rheumatoid arthritis. Pak J Pharm Sci 2015;28:185-93.  Back to cited text no. 27
    
28.
Baviskar DT, Parik VB, Jain DJ Development of matrix-type transdermal delivery of lornoxicam: In vitro evaluation and pharmacodynamic and pharmacokinetic studies in albino rats. Pda J Pharm Sci Technol 2013;67:9-22.  Back to cited text no. 28
    
29.
Gurtovenko AA, Anwar J Modulating the structure and properties of cell membranes: The molecular mechanism of action of dimethyl sulfoxide. J Phys Chem B 2007;111:10453-60.  Back to cited text no. 29
    
30.
Notman R, Noro M, O’Malley B, Anwar J Molecular basis for dimethylsulfoxide (Dmso) action on lipid membranes. J Am Chem Soc 2006;128:13982-3.  Back to cited text no. 30
    
31.
de Ménorval MA, Mir LM, Fernández ML, Reigada R Effects of dimethyl sulfoxide in cholesterol-containing lipid membranes: A comparative study of experiments in silico and with cells. PLoS One 2012;7:e41733.  Back to cited text no. 31
    


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7]
 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4], [Table 5]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract
Introduction
Materials and Me...
Results
Discussion
Conclusion
References
Article Figures
Article Tables

 Article Access Statistics
    Viewed35    
    Printed2    
    Emailed0    
    PDF Downloaded6    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]